#leqembi — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #leqembi, aggregated by home.social.
-
https://www.europesays.com/es/787597/ Identifican proteínas sanguíneas que podrían medir los efectos de un tratamiento contra el Alzheimer #alzheimer #biomarcadores #ES #España #Health #lecanemab #leqembi #ProteínaAmiloide #Salud #Spain #TheLancetNeurology
-
https://www.europesays.com/it/669574/ Alzheimer, qualcosa sta cambiando davvero: il test che può “vedere” la malattia prima dei sintomi #Adacanumab #APOEε4 #donanemab #FaustoFantò #Health #IT #Italia #Italy #Kisunla #lecanemab #Leqembi #orbassano #PTau217 #Salute #SanLuigiGonzaga
-
https://www.europesays.com/it/665815/ Alzheimer, la cura non sarà una sola: amiloide, tau e infiammazione, che cosa cambia davvero #AlJerdiS #Alzheimer #APOE4 #BetaAmiloide #demenza #donanemab #Health #IT #Italia #Italy #KimAY #Kisunla #lecanemab #Leqembi #MacDonaldR #ProteinaTau #Salute #TerapieDemenza #UnioneEuropea
-
https://www.europesays.com/at/328468/ Alzheimer: IBC-Ab002 zeigt frühe Sicherheit – FDA macht Lecanemab per Autoinjektor leichter #AI #Alzheimers #Antikörper #ARTIFICIALINTELLIGENCE #AT #Austria #Autoinjektor #Biomarker #Bluttest #Diagnostik #FDA #Forschung #Gesundheit #Health #KI #KlinischeStudie #KünstlicheIntelligenz #Lecanemab #Leqembi #Mikroglia #Österreich #PDL1 #Phase1 #Subkutan
-
https://www.europesays.com/ch/86909/ Takeda, Innovent-Lilly, Roche—Fierce Pharma Asia #Asia #Astellas #BiotechnologyInnovationOrganization #BoehringerIngelheim #china #Chugai #Eisai #FDA #FiercePharmaAsia #FiercePharmaHomepage #Form483 #GLP1 #InnoventBiologics #KyowaKirin #Lenvima #Leqembi #LicensingDeals #Pharma #Roche #SamsungBioepis #Takeda #WuXiAppTec
-
https://www.europesays.com/ch/33287/ Novartis, SciNeuro to work together on preclinical amyloid-targeting drug for Alzheimer’s #Alzheimer #Deals #Leqembi #Novartis #R&D
-
https://www.europesays.com/at/43717/ Eisai präsentiert neue Langzeitdaten zu Alzheimer-Mittel Leqembi #AlzheimerForschung #AlzheimerMittel #ApoE4 #AT #Austria #Eisai #Gesundheit #Health #Langzeitdaten #Leqembi #Österreich #patienten #Risikogen #Studienergebnisse #Therapien
-
Lees tip -> Zorginstituut: lecanemab geen meerwaarde bij Alzheimer | Lecanemab vertraagt Alzheimer nauwelijks, kent risico’s en wordt daarom niet geadviseerd voor vergoeding. | #Alzheimer #basispakket #lecanemab #Leqembi #ZorginstituutNederland |
https://hbpmedia.nl/zorginstituut-lecanemab-geen-meerwaarde-bij-alzheimer/
-
Lees tip -> Zorginstituut: lecanemab geen meerwaarde bij Alzheimer | Lecanemab vertraagt Alzheimer nauwelijks, kent risico’s en wordt daarom niet geadviseerd voor vergoeding. | #Alzheimer #basispakket #lecanemab #Leqembi #ZorginstituutNederland |
https://hbpmedia.nl/zorginstituut-lecanemab-geen-meerwaarde-bij-alzheimer/
-
https://www.europesays.com/uk/651465/ China’s new commercial insurance model could broaden access to Alzheimer’s drugs #Alzheimer #China #Eisai #EliLilly #Health #Healthcare #Kisunla #Leqembi #pharma #UK #UnitedKingdom
-
https://www.europesays.com/ie/248004/ China’s new commercial insurance model could broaden access to Alzheimer’s drugs #Alzheimer #China #Éire #Eisai #EliLilly #Health #HealthCare #Healthcare #IE #Ireland #Kisunla #Leqembi #pharma
-
[07:10 PM] New Alzheimer's drug: only a few eligible for treatment
It is estimated that less than one in ten people with dementia are eligible for treatment with Lecanemab or Leqembi, the slowing agent that is still allowed on the European market by the European M
https://nltimes.nl/2024/11/16/new-alzheimers-drug-eligible-treatment
#lessthanone #ten #Lecanemab #Leqembi #European #theEuropeanM -
[07:10 PM] New Alzheimer's drug: only a few eligible for treatment
It is estimated that less than one in ten people with dementia are eligible for treatment with Lecanemab or Leqembi, the slowing agent that is still allowed on the European market by the European M
https://nltimes.nl/2024/11/16/new-alzheimers-drug-eligible-treatment
#lessthanone #ten #Lecanemab #Leqembi #European #theEuropeanM -
Ein Medikament zum Vergessen.
»Leqembi kann #Alzheimer weder stoppen noch heilen.«
Viele Menschen mit Alzheimer haben auf #Leqembi gehofft, das Medikament ist in den USA bereits erhältlich. Doch die Europäische Arzneimittel-Agentur sieht von einer Zulassung ab.
-
Ein Medikament zum Vergessen.
»Leqembi kann #Alzheimer weder stoppen noch heilen.«
Viele Menschen mit Alzheimer haben auf #Leqembi gehofft, das Medikament ist in den USA bereits erhältlich. Doch die Europäische Arzneimittel-Agentur sieht von einer Zulassung ab.
-
Ein Medikament zum Vergessen.
»Leqembi kann #Alzheimer weder stoppen noch heilen.«
Viele Menschen mit Alzheimer haben auf #Leqembi gehofft, das Medikament ist in den USA bereits erhältlich. Doch die Europäische Arzneimittel-Agentur sieht von einer Zulassung ab.
-
2/2
The United States, Israel, and several Asian countries have approved #Leqembi, but on 26 July the European Medicines Agency announced its benefit in clinical trials was small and does not counterbalance the risk of serious harm. The decision comes weeks after the U.S. Food and Drug Administration approved a second antiamyloid antibody with a similar profile, #donanemab, and as Leqembi’s popularity is growing in the United States.Science, 2 August 2024
-
2/2
The United States, Israel, and several Asian countries have approved #Leqembi, but on 26 July the European Medicines Agency announced its benefit in clinical trials was small and does not counterbalance the risk of serious harm. The decision comes weeks after the U.S. Food and Drug Administration approved a second antiamyloid antibody with a similar profile, #donanemab, and as Leqembi’s popularity is growing in the United States.Science, 2 August 2024
-
2/2
The United States, Israel, and several Asian countries have approved #Leqembi, but on 26 July the European Medicines Agency announced its benefit in clinical trials was small and does not counterbalance the risk of serious harm. The decision comes weeks after the U.S. Food and Drug Administration approved a second antiamyloid antibody with a similar profile, #donanemab, and as Leqembi’s popularity is growing in the United States.Science, 2 August 2024
-
2/2
The United States, Israel, and several Asian countries have approved #Leqembi, but on 26 July the European Medicines Agency announced its benefit in clinical trials was small and does not counterbalance the risk of serious harm. The decision comes weeks after the U.S. Food and Drug Administration approved a second antiamyloid antibody with a similar profile, #donanemab, and as Leqembi’s popularity is growing in the United States.Science, 2 August 2024
-
2/2
The United States, Israel, and several Asian countries have approved #Leqembi, but on 26 July the European Medicines Agency announced its benefit in clinical trials was small and does not counterbalance the risk of serious harm. The decision comes weeks after the U.S. Food and Drug Administration approved a second antiamyloid antibody with a similar profile, #donanemab, and as Leqembi’s popularity is growing in the United States.Science, 2 August 2024
-
European drug regulators have withheld approval for a new #Alzheimer’s disease therapy, underscoring deep divisions about a treatment that’s generating both excitement and concern. Infusions of the monoclonal antibody, marketed as #Leqembi by the companies Eisai and Biogen, help clear a toxic protein called beta amyloid from the brain and modestly slow progression of the fatal disease. But the drug comes with considerable risks, including brain swelling and bleeding.
1/2
Science, 2 August 2024 -
European drug regulators have withheld approval for a new #Alzheimer’s disease therapy, underscoring deep divisions about a treatment that’s generating both excitement and concern. Infusions of the monoclonal antibody, marketed as #Leqembi by the companies Eisai and Biogen, help clear a toxic protein called beta amyloid from the brain and modestly slow progression of the fatal disease. But the drug comes with considerable risks, including brain swelling and bleeding.
1/2
Science, 2 August 2024 -
European drug regulators have withheld approval for a new #Alzheimer’s disease therapy, underscoring deep divisions about a treatment that’s generating both excitement and concern. Infusions of the monoclonal antibody, marketed as #Leqembi by the companies Eisai and Biogen, help clear a toxic protein called beta amyloid from the brain and modestly slow progression of the fatal disease. But the drug comes with considerable risks, including brain swelling and bleeding.
1/2
Science, 2 August 2024 -
European drug regulators have withheld approval for a new #Alzheimer’s disease therapy, underscoring deep divisions about a treatment that’s generating both excitement and concern. Infusions of the monoclonal antibody, marketed as #Leqembi by the companies Eisai and Biogen, help clear a toxic protein called beta amyloid from the brain and modestly slow progression of the fatal disease. But the drug comes with considerable risks, including brain swelling and bleeding.
1/2
Science, 2 August 2024 -
European drug regulators have withheld approval for a new #Alzheimer’s disease therapy, underscoring deep divisions about a treatment that’s generating both excitement and concern. Infusions of the monoclonal antibody, marketed as #Leqembi by the companies Eisai and Biogen, help clear a toxic protein called beta amyloid from the brain and modestly slow progression of the fatal disease. But the drug comes with considerable risks, including brain swelling and bleeding.
1/2
Science, 2 August 2024 -
European Medicines Agency approves 14 new medicines but rejects new Alzheimer’s drug https://www.euractiv.com/section/health-consumers/news/european-medicines-agency-approves-14-new-medicines-but-rejects-new-alzheimers-drug/?utm_source=dlvr.it&utm_medium=mastodon #AlzheimersDisease #Biogen #Eisai #Leqembi #novonordisk
-
European Medicines Agency approves 14 new medicines but rejects new Alzheimer’s drug https://www.euractiv.com/section/health-consumers/news/european-medicines-agency-approves-14-new-medicines-but-rejects-new-alzheimers-drug/?utm_source=dlvr.it&utm_medium=mastodon #AlzheimersDisease #Biogen #Eisai #Leqembi #novonordisk
-
European Medicines Agency approves 14 new medicines but rejects new Alzheimer’s drug https://www.euractiv.com/section/health-consumers/news/european-medicines-agency-approves-14-new-medicines-but-rejects-new-alzheimers-drug/?utm_source=dlvr.it&utm_medium=mastodon #AlzheimersDisease #Biogen #Eisai #Leqembi #novonordisk
-
Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi is facing an unexpected hurdle to widespread use. https://www.japantimes.co.jp/news/2024/04/24/world/science-health/alzheimer-drug-us-adoption-slow/ #worldnews #sciencehealth #alzheimers #brain #eisai #biogen #leqembi #us
-
Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi is facing an unexpected hurdle to widespread use. https://www.japantimes.co.jp/news/2024/04/24/world/science-health/alzheimer-drug-us-adoption-slow/ #worldnews #sciencehealth #alzheimers #brain #eisai #biogen #leqembi #us
-
Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi is facing an unexpected hurdle to widespread use. https://www.japantimes.co.jp/news/2024/04/24/world/science-health/alzheimer-drug-us-adoption-slow/ #worldnews #sciencehealth #alzheimers #brain #eisai #biogen #leqembi #us
-
Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi is facing an unexpected hurdle to widespread use. https://www.japantimes.co.jp/news/2024/04/24/world/science-health/alzheimer-drug-us-adoption-slow/ #worldnews #sciencehealth #alzheimers #brain #eisai #biogen #leqembi #us
-
Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi is facing an unexpected hurdle to widespread use. https://www.japantimes.co.jp/news/2024/04/24/world/science-health/alzheimer-drug-us-adoption-slow/ #worldnews #sciencehealth #alzheimers #brain #eisai #biogen #leqembi #us
-
"I think one of the reasons Leqembi was approved (and Lilly's donanemab is likely to be, this year) is that aducanumab was approved. I remain skeptical that these drugs will provide any real-world benefit, but I am not skeptical at all of the sales potentials for both of them."
#Alzheimer
#Leqembi
#aducanumabhttps://www.science.org/content/blog-post/goodbye-aduhelm?s=09
-
"I think one of the reasons Leqembi was approved (and Lilly's donanemab is likely to be, this year) is that aducanumab was approved. I remain skeptical that these drugs will provide any real-world benefit, but I am not skeptical at all of the sales potentials for both of them."
#Alzheimer
#Leqembi
#aducanumabhttps://www.science.org/content/blog-post/goodbye-aduhelm?s=09
-
"I think one of the reasons Leqembi was approved (and Lilly's donanemab is likely to be, this year) is that aducanumab was approved. I remain skeptical that these drugs will provide any real-world benefit, but I am not skeptical at all of the sales potentials for both of them."
#Alzheimer
#Leqembi
#aducanumabhttps://www.science.org/content/blog-post/goodbye-aduhelm?s=09
-
"I think one of the reasons Leqembi was approved (and Lilly's donanemab is likely to be, this year) is that aducanumab was approved. I remain skeptical that these drugs will provide any real-world benefit, but I am not skeptical at all of the sales potentials for both of them."
#Alzheimer
#Leqembi
#aducanumabhttps://www.science.org/content/blog-post/goodbye-aduhelm?s=09
-
"I think one of the reasons Leqembi was approved (and Lilly's donanemab is likely to be, this year) is that aducanumab was approved. I remain skeptical that these drugs will provide any real-world benefit, but I am not skeptical at all of the sales potentials for both of them."
#Alzheimer
#Leqembi
#aducanumabhttps://www.science.org/content/blog-post/goodbye-aduhelm?s=09
-
Ein neues Medikament soll mal wieder #Alzheimer verlangsamen, zahlreiche Medien feiern #Leqembi bereits als «Durchbruch» und «grosse Hoffnung für Alzheimerpatient:innen weltweit».
Dabei läuft hier einfach nur mal wieder eine professionelle, weltweit orchestrierte Werbekampagne der Pharmaindustrie und viele Journalisten gehen dieser PR-Strategie wieder und wieder auf den Leim ....
Eine rühmliche Ausnahme zu den seichten Lobeshymmnen findet sich hier:
https://www.infosperber.ch/gesundheit/mediziner-warnen-vor-neuem-alzheimer-medikament/ -
Ein neues Medikament soll mal wieder #Alzheimer verlangsamen, zahlreiche Medien feiern #Leqembi bereits als «Durchbruch» und «grosse Hoffnung für Alzheimerpatient:innen weltweit».
Dabei läuft hier einfach nur mal wieder eine professionelle, weltweit orchestrierte Werbekampagne der Pharmaindustrie und viele Journalisten gehen dieser PR-Strategie wieder und wieder auf den Leim ....
Eine rühmliche Ausnahme zu den seichten Lobeshymmnen findet sich hier:
https://www.infosperber.ch/gesundheit/mediziner-warnen-vor-neuem-alzheimer-medikament/ -
Ein neues Medikament soll mal wieder #Alzheimer verlangsamen, zahlreiche Medien feiern #Leqembi bereits als «Durchbruch» und «grosse Hoffnung für Alzheimerpatient:innen weltweit».
Dabei läuft hier einfach nur mal wieder eine professionelle, weltweit orchestrierte Werbekampagne der Pharmaindustrie und viele Journalisten gehen dieser PR-Strategie wieder und wieder auf den Leim ....
Eine rühmliche Ausnahme zu den seichten Lobeshymmnen findet sich hier:
https://www.infosperber.ch/gesundheit/mediziner-warnen-vor-neuem-alzheimer-medikament/ -
Dilemma: Will Leqembi ™ prolong quality of life, or more suffering?
"When FDA approves a new cancer agent, oncologists usually ask: will it prolong duration of good quality life, or just prolong duration of suffering, and will the side effects profile be tolerable enough whether it works or not?
"Those kinds of questions seem pertinent to the new Alzheimer’s Disease (AD) medication, lecanemab, marketed now as Leqembi ™. "
#alzheimer #lecanemab #leqembi
https://caregivingoldguy.website/2023/08/07/dilemma-will-leqembi-tm-prolong-quality-of-life-or-more-suffering/ -
Dilemma: Will Leqembi ™ prolong quality of life, or more suffering?
"When FDA approves a new cancer agent, oncologists usually ask: will it prolong duration of good quality life, or just prolong duration of suffering, and will the side effects profile be tolerable enough whether it works or not?
"Those kinds of questions seem pertinent to the new Alzheimer’s Disease (AD) medication, lecanemab, marketed now as Leqembi ™. "
#alzheimer #lecanemab #leqembi
https://caregivingoldguy.website/2023/08/07/dilemma-will-leqembi-tm-prolong-quality-of-life-or-more-suffering/ -
Dilemma: Will Leqembi ™ prolong quality of life, or more suffering?
"When FDA approves a new cancer agent, oncologists usually ask: will it prolong duration of good quality life, or just prolong duration of suffering, and will the side effects profile be tolerable enough whether it works or not?
"Those kinds of questions seem pertinent to the new Alzheimer’s Disease (AD) medication, lecanemab, marketed now as Leqembi ™. "
#alzheimer #lecanemab #leqembi
https://caregivingoldguy.website/2023/08/07/dilemma-will-leqembi-tm-prolong-quality-of-life-or-more-suffering/ -
Dilemma: Will Leqembi ™ prolong quality of life, or more suffering?
"When FDA approves a new cancer agent, oncologists usually ask: will it prolong duration of good quality life, or just prolong duration of suffering, and will the side effects profile be tolerable enough whether it works or not?
"Those kinds of questions seem pertinent to the new Alzheimer’s Disease (AD) medication, lecanemab, marketed now as Leqembi ™. "
#alzheimer #lecanemab #leqembi
https://caregivingoldguy.website/2023/08/07/dilemma-will-leqembi-tm-prolong-quality-of-life-or-more-suffering/ -
Dilemma: Will Leqembi ™ prolong quality of life, or more suffering?
"When FDA approves a new cancer agent, oncologists usually ask: will it prolong duration of good quality life, or just prolong duration of suffering, and will the side effects profile be tolerable enough whether it works or not?
"Those kinds of questions seem pertinent to the new Alzheimer’s Disease (AD) medication, lecanemab, marketed now as Leqembi ™. "
#alzheimer #lecanemab #leqembi
https://caregivingoldguy.website/2023/08/07/dilemma-will-leqembi-tm-prolong-quality-of-life-or-more-suffering/ -
FDA Approves First Drug Shown to Slow Down Alzheimer’s Progression
#Health #Alzheimer #FDA #FoodAndDrugAdministration #Leqembi #Drug #Dementia #Memory #MedicareCoverage
https://the-14.com/fda-approves-first-drug-shown-to-slow-down-alzheimers-progression/ -
The US Food and Drug Administration has given full approval for a drug they say can slow the progression of Alzheimer's disease.The incurable neurological di...
US government approves Alzheimer’s drug to slow cognitive decline -
The US Food and Drug Administration has given full approval for a drug they say can slow the progression of Alzheimer's disease.The incurable neurological di...
US government approves Alzheimer’s drug to slow cognitive decline -
The US Food and Drug Administration has given full approval for a drug they say can slow the progression of Alzheimer's disease.The incurable neurological di...
US government approves Alzheimer’s drug to slow cognitive decline -
The US Food and Drug Administration has given full approval for a drug they say can slow the progression of Alzheimer's disease.The incurable neurological di...
US government approves Alzheimer’s drug to slow cognitive decline -
The US Food and Drug Administration has given full approval for a drug they say can slow the progression of Alzheimer's disease.The incurable neurological di...
US government approves Alzheimer’s drug to slow cognitive decline -
The next big thing in Alzheimer’s treatment didn’t reverse symptoms in any trial participants. It’s expensive. And, critics say, it will deepen racial disparities in care for Black patients.
#Alzheimers #leqembi #HealthDisparities -
The next big thing in Alzheimer’s treatment didn’t reverse symptoms in any trial participants. It’s expensive. And, critics say, it will deepen racial disparities in care for Black patients.
#Alzheimers #leqembi #HealthDisparities -
The next big thing in Alzheimer’s treatment didn’t reverse symptoms in any trial participants. It’s expensive. And, critics say, it will deepen racial disparities in care for Black patients.
#Alzheimers #leqembi #HealthDisparities
